[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354081-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354081-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-impact-of-novel-cardiovascular-and-immune-system-dosimetric-parameters-in-stage-iii-nsclc-patients-treated-with-radiotherapy","Clinical impact of novel cardiovascular and immune system dosimetric parameters in stage III NSCLC patients treated with radiotherapy","","Purpose To evaluate the clinical impact of dose to structures not routinely constrained in stage III NSCLC radiotherapy (RT), including the left anterior descending artery (LAD) and the estimated dose to immune cells (EDIC). Materials/Methods A retrospective IRB-approved cohort of consecutive stage III NSCLC patients treated with definitive RT between 2012 and 2022. LAD was manually contoured; EDIC was calculated using Jin’s model. Overall survival (OS) was primary endpoint with Kaplan-Meier, Cox regression, and ROC cutoff DVH analysis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-impact-of-novel-cardiovascular-and-immune-system-dosimetric-parameters-in-stage-iii-nsclc-patients-treated-with-radiotherapy/354081/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-impact-of-novel-cardiovascular-and-immune-system-dosimetric-parameters-in-stage-iii-nsclc-patients-treated-with-radiotherapy/354081.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical structures were evaluated in this stage III NSCLC RT study?","Question",{"text":63,"@type":64},"The study evaluated the left anterior descending artery (LAD) and the estimated dose to immune cells (EDIC), which are not routinely constrained in RT planning.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were LAD and EDIC determined for patients in the dataset?",{"text":68,"@type":64},"LAD was manually contoured following published guidelines, while EDIC was calculated using the model by Jin.",{"name":70,"@type":61,"acceptedAnswer":71},"Which dosimetric parameters were significantly associated with overall survival?",{"text":72,"@type":64},"In multivariate analysis, EDIC as a continuous variable, mean heart dose (MHD), EDIC ≥ 5 Gy, MHD \u003C 10 Gy, and LAD V15 \u003C 47.5% were significantly associated with overall survival. PTV was linked to EDIC > 5 Gy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354081,1790667290,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Dionisi et al. Radiation Oncology (2026) 21:66 [https://doi.org/10.1186/s13014-026-02835-8](https://doi.org/10.1186/s13014-026-02835-8)  \nRadiation Oncology  \nRESEARCH Open Access  \nClinical impact of novel cardiovascular and immune system dosimetric parameters in stage III NSCLC patients treated  \nwith radiotherapy  \nFrancesco Dionisi1*, Giulia Mascari2, Isabella Sperduti3, Lucia Goanta1, Alessia Nardangeli 1, Pedro Ordonez4, Marco D’Andrea4, Antonella Soriani4 and Giuseppe Sanguineti1  \nAbstract  \nPurpose To evaluate the clinical impact ofthe dose to structures not routinely constrained in the radiation treatment (RT) of stage III NSCLC, such as the left anterior descending artery (LAD) and the estimated dose to the immune cells (EDIC) .  \nMaterials/Methods The dataset of all consecutive patients affected by stage III NSCLC and treated with definitive RT between 2012 and 2022 at our Institution were retrieved in this IRB approved retrospective study. The LAD was manually contoured following published guidelines. EDIC was calculated according to the model by Jin. Overall Survival (OS) was the primary endpoint of the study. Kaplan-Meier and Cox logistic regression statistics were used. Receiver operating characteristic curves evaluated cutoff DVH values.  \nResults 108 patients were analyzed with a median follow-up of 52 months (95% CI 27.5–76. 5) . Median RT dose was 60 Gy (54–69 .3 Gy) . Median OS was 29 months (95% CI 10.2–47. 8) . On multivariate analysis, when evaluating the EDIC as a continuous variable, EDIC (HR 1.4, 95% CI 1.08–1. 8, P = 0 . 009) and mean heart dose (MHD) \u003C 10 Gy (HR 1. 8, 95% CI 1.0-3. 2, P = 0 . 03) were significantly associated with OS. When the EDIC was evaluated as a categorical variable, EDIC ≥ 5 Gy (HR 2 . 2, 95% CI 1.2–4. 1, P = 0 . 008), MHD \u003C 10 (HR 1. 9, 95% CI 1.1–3. 2, P = 0 . 01) and LAD V15 \u003C 47. 5%(HR 0 . 5, 95% CI 0 .2–0. 9, P = 0 . 02) were significantly associated with OS. PTV was the only parameter significantly associated with EDIC > 5 Gy (HR 16,6 95% CI 4 .5–61. 3, P \u003C 0. 001), with a cutoff value of 457.1 cc.  \nConclusions The relevant impact ofthe EDIC on the outcome of stage III NSCLC patients treated with RT is confirmed. The EDIC threshold of 5 Gy here reported merits prospective validation. Our results also reinforced the importance of LAD contouring and optimization in the clinical practice of RT for stage III NSCLC patients.  \n*Correspondence:  \nFrancesco Dionisi  \n[francescodionisi2@gmail.com](francescodionisi2@gmail.com)  \n1Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy  \n2Radiation Oncology, University of Perugia and Perugia General Hospital, Perugia, Italy  \n3Biostatistics, IRCCS Regina Elena National Cancer Institute, Rome, Italy 4Laboratory of Medical Physics and Expert Systems, IRCCS Regina Elena National Cancer Institute, Rome, Italy  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/li","cbCainhQ3JGjiJi2","https://ap.wps.com/l/cbCainhQ3JGjiJi2","pdf",1568575,12,"English","# Abstract\n## Purpose\n## Materials/Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What clinical structures were evaluated in this stage III NSCLC RT study?\",\"answer\":\"The study evaluated the left anterior descending artery (LAD) and the estimated dose to immune cells (EDIC), which are not routinely constrained in RT planning.\"},{\"question\":\"How were LAD and EDIC determined for patients in the dataset?\",\"answer\":\"LAD was manually contoured following published guidelines, while EDIC was calculated using the model by Jin.\"},{\"question\":\"Which dosimetric parameters were significantly associated with overall survival?\",\"answer\":\"In multivariate analysis, EDIC as a continuous variable, mean heart dose (MHD), EDIC ≥ 5 Gy, MHD \\u003c 10 Gy, and LAD V15 \\u003c 47.5% were significantly associated with overall survival. PTV was linked to EDIC \\u003e 5 Gy.\"}]","Clinical impact of novel cardiovascular and immune system dosimetric parameters in stage III NSCLC patients treated with radiotherapy | PDF",1790108796,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2aa0144f9f36ec57951f5d391d296b6.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbe00774b31ebc618e879715a748c7c5.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c4549bd7e7873410485e05ce72eb070.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e04a82fade8ee7bd1d69327bea14610.webp",980,1306]